- Article
A Single-Center Review of Infusion-Associated Reactions in Patients with CLN2 Disease Receiving Cerliponase Alfa
- Rebecca Whiteley,
- Megan Keating,
- Mel McSweeney,
- Megan Dorman,
- Mathilda Antonini,
- Spyros Batzios,
- Emma Footitt,
- Laura Lee-Clark and
- Paul Gissen
Background: Cerliponase alfa is an intracerebroventricular (ICV) enzyme replacement therapy (ERT) and the only approved treatment for neuronal ceroid lipofuscinosis type 2 (CLN2) disease. While generally well tolerated, infusion-associated reactions...

